Vaccine News and Research

Latest Vaccine News and Research

Single-parent status, household income linked to increased rate of hospital readmissions of asthmatic children

Financial strain and competing priorities at home may contribute to the greater number of hospital readmissions of children with asthma from single-parent homes compared to dual-parent households, according to a new study presented at the American College of Allergy, Asthma and Immunology Annual Meeting in Boston, Nov. 3-8.

5 Nov 2011

International research explains why measles virus spreads so quickly

An international collaboration involving Inserm has revealed how the measles virus leaves the body of an infected person to contaminate another individual. The researchers have identified a key receptor, located in the trachea, which allows the virus to spread through the air rapidly from one organism to another. The receptor, nectine-4, is also known to be a biomarker for some cancers.

5 Nov 2011

Global Task Force report presents 'compelling' action on cancer care, control

"More than 50 percent of all new cancers and two-thirds of the annual cancer mortality worldwide happen in low-income and middle-income countries," a Lancet editorial states and describes how the recently released report Closing the Cancer Divide, by the Global Task Force on Expanded Access to Cancer Care and Control in Developing Countries, "presents a compelling case for comprehensive action on expanded access to cancer care and control with realistic recommendations that will be beneficial beyond cancer."

5 Nov 2011

Study finds increase in cervical cancer incidence among young British women

The incidence of cervical cancer in women in their 20s has risen by over 40 per cent between 1992 and 2006 in England, despite the overall incidence of cervical cancer dropping by 30 per cent, according to research that will be presented at the annual National Cancer Research Institute (NCRI) Cancer Conference in Liverpool which starts tomorrow.

5 Nov 2011

Idera raises $9.5M in convertible preferred stock offering

Idera Pharmaceuticals, Inc. today announced it has raised $9.5 million in a convertible preferred stock offering.

5 Nov 2011

Viewpoints: Romney's plan to cut the debt; congressional squabbles on spending; spurning insurers' concerns about new labels

First, eliminate every government program that is not absolutely essential. There are many things government does that we may like but that we do not need. … For example: Repeal ObamaCare, which would save $95 billion in 2016. …Eliminate Title X family planning programs benefiting abortion groups like Planned Parenthood. … Second, return federal programs to the states where innovation, cost management and reduction of fraud and abuse can far exceed what Washington achieves. I will block grant Medicaid and workforce training, saving well over $100 billion in 2016.

5 Nov 2011

Experts look to India to develop accurate, affordable TB diagnostics

SciDev.Net examines tuberculosis (TB) in India, which has the world's highest TB burden, and some experts' hopes that researchers in the country can develop accurate and affordable diagnostic test kits.

4 Nov 2011

Inhibitex third quarter revenue increases to $1.3 million

Inhibitex, Inc. today announced its financial results for the third quarter ended September 30, 2011 and provided an update on several recent corporate developments, including top-line safety and antiviral data from the first cohort in its ongoing clinical trial designed to evaluate higher doses of INX-189, an oral nucleotide polymerase inhibitor, being developed to treat chronic infections caused by hepatitis C virus (HCV), administered as monotherapy or in combination with ribavirin for seven days.

4 Nov 2011

Important to keep obstacles to malaria control in mind as research moves forward

In a post in the Center for Strategic & International Studies' "Smart Global Health" blog, Julia Nagel, web and social media assistant at the Global Health Policy Center, examines "the obstacles that global malaria control efforts face," writing that "eradicating malaria is complex and difficult" because "there are four species of human malaria" that "respond differently to medicines, exhibit drug resistance in different ways, and most importantly, make finding a fool-proof vaccine against all malaria nearly impossible."

4 Nov 2011

Measles virus develops a strategy of diabolic elegance

Mayo Clinic researchers have discovered why measles, perhaps the most contagious viral disease in the world, spreads so quickly. The virus emerges in the trachea of its host, provoking a cough that fills the air with particles ready to infect the next host. The findings may also help in the fight against ovarian, breast and lung cancers.

3 Nov 2011

Study outlines evolution of malaria, leishmaniasis and trypanosomiasis

One of the most comprehensive analyses yet done of the ancient history of insect-borne disease concludes for the first time that malaria is not only native to the New World, but it has been present long before humans existed and has evolved through birds and monkeys.

3 Nov 2011

EBV vaccine could prevent mononucleosis and cancers linked to virus

In a new article from the National Institutes of Health (NIH), Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), and Harold Varmus, M.D., director of the National Cancer Institute (NCI), join Gary Nabel, M.D., Ph.D., director of NIAID's Vaccine Research Center, and Jeffrey Cohen, M.D., chief of NIAID's Laboratory of Infectious Diseases, in summarizing a recent meeting of experts who gathered to map directions toward an EBV vaccine.

3 Nov 2011

New version of chitosan effective in capturing flu virus

With flu season just around the corner, scientists are reporting development of a new material for the fiber in face masks, air conditioning filters and air cleaning filters that captures influenza viruses before they can get into people's eyes, noses and mouths and cause infection. The report on the fiber appears in ACS' journal Biomacromolecules.

3 Nov 2011

IP-K and Sanofi form new HBV research collaboration

One of the most common and serious infectious diseases, Hepatitis B, is to be targeted in a new collaborative venture between the internationally-renowned translational research institute, Institut Pasteur Korea (IP-K), and the Korean arm of the leading global healthcare company, Sanofi-Aventis Korea. The goal is to develop and validate a high throughput assay to screen IP-K's chemical libraries for novel compounds that can be developed as new drugs.

3 Nov 2011

Viewpoints: GOP intransigence on super committee; taxing health benefits would backfire; the need for care in defining essential benefits

There may be logic to Speaker John Boehner's insidious intransigence. Republicans keep saying no and Democrats keep offering more concessions. Super committee Republicans suggested instead a package based largely on cuts in Medicare, Medicaid and Social Security, combined with magical hundreds of billions they say would be produced by slashing assistance to the elderly and the vulnerable, by selling off government assets, and by the growth sparked by tax cuts.

3 Nov 2011

New protein microarray technology could eradicate malaria

A new research technology is revealing how humans develop immunity to malaria, and could assist programs aimed at eradicating this parasitic disease.

2 Nov 2011

Viewpoints: Super committee clock is ticking; replacing CLASS; 'personhood' amendment in Miss.

There are only three weeks left for the Congressional supercommittee to come up with a plan to reduce the federal deficit by at least $1.2 trillion, and there is no sign that the panel is anywhere close to reaching an agreement. Only one side, in fact, seems to be trying - the Democrats - and it is being far too accommodating, given the fierce obstructionism of the other side, the Republicans.

2 Nov 2011

GSK, Alnylam collaborate to apply VaxiRNA technology for influenza vaccine production

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today it has formed a collaboration with GlaxoSmithKline (GSK) focused on Alnylam's VaxiRNATM technology for certain GSK vaccine products, including influenza. VaxiRNA is a new RNAi technology for the enhanced production of viruses used in the manufacture of vaccine products. GSK, a leading vaccine manufacturer, is the first company to form a collaboration accessing this new platform.

2 Nov 2011

Henry Schein third quarter net sales increase 11.5% to $2.1 billion

Henry Schein, Inc., the largest provider of healthcare products and services to office-based practitioners, today reported record financial results for the quarter ended September 24, 2011.

1 Nov 2011

Countries need vigilance, informed media coverage to achieve polio eradication

In this SciDev.Net editorial, T.V. Padma, regional coordinator for South Asia for the news service, recaps findings from the latest report of the Independent Monitoring Board of the Global Polio Eradication Initiative (GPEI), released last week, and writes, "Polio control in developing countries has received massive international support and funding, including free supplies of vaccines. Yet transmission of the virus remains. Clearly, there are problems other than funds."

1 Nov 2011